共 241 条
[1]
Ballestrero A(2012)Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond Curr Cancer Drug Targets 12 316-328
[2]
Garuti A(2008)K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 1757-1765
[3]
Cirmena G(2010)Ras-induced resistance to lapatinib is overcome by MEK inhibition Curr Cancer Drug Targets 10 168-175
[4]
Rocco I(2009)Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 1408-1417
[5]
Palermo C(2015)Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials Ann Oncol 26 13-21
[6]
Nencioni A(2015)Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis Eur J Cancer 51 587-594
[7]
Karapetis CS(2009)PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies Cancer Res 69 1851-1857
[8]
Khambata-Ford S(2014)Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial Ann Oncol 25 1756-1761
[9]
Jonker DJ(2009)Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm Nat Protoc 4 1073-1081
[10]
O’Callaghan CJ(2013)Predicting functional effect of human missense mutations using PolyPhen-2 Curr Protocols Hum Genet. Chapter 7 20-22